Dr. Rapaka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 667-214-1515Fax+1 410-328-8326
Education & Training
University of MarylandFellowship, Infectious Disease, 2018
Johns Hopkins UniversityResidency, Internal Medicine, 2011 - 2014
University of Pittsburgh School of MedicineClass of 2010
Certifications & Licensure
MD State Medical License 2018 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- 2 citationsSARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.Kanal Singh, Kevin Rubenstein, Viviane Callier, Katy Shaw-Saliba, Adam Rupert
The Journal of Infectious Diseases. 2024-09-23 - How do adjuvants enhance immune responses?Rekha R Rapaka
Elife. 2024-08-13 - 6 citationsEfficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.Kirsten E Lyke, Joel V Chua, Michael Koren, Heather Friberg, Gregory D Gromowski
The Lancet. Infectious Diseases. 2024-08-01
Press Mentions
The AMA Does Not Speak for UsDecember 9th, 2016
Grant Support
- Determinants Of Antibody-Based Host Resistance Against Pneumocystis CariniiNational Institute Of Environmental Health Sciences2008–2009
- Determinants Of Antibody-Based Host Resistance Against Pneumocystis CariniiNational Institute Of Environmental Health Sciences2006–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
